IDWeek 2013: Pediatric Infectious Diseases

HIV Prophylaxis with twice-daily lopinavir/ritonavir was well tolerated in high-risk neonates without adverse drug events, as reported at IDWeek 2013.

Antifungal prophylaxis is associated with significant reduction in induction mortality rates in pediatric patients with acute myeloid leukemia (AML) and reduced supportive care resources utilization.

Combination fluoroquinolone plus probiotic for the eradication of Quiescent Intracellular Reservoirs (QIRs) resulted in a decrease of recurrent urinary tract infections (UTI) in pediatric patients.

After the publication of PIDS/IDSA treatment guidelines for community acquired pneumonia (CAP), the use of recommended antibiotic therapies is increasing for children hospitalized with CAP, results presented at IDWeek 2013.

Results of a prospective study presented at IDWeek 2013 demonstrate that live attenuated vaccines administered to pediatric liver transplant recipients are well tolerated.

The increased use of liposomal amphotericin B (L-AMB) in neonates has occurred without evidence of increased efficacy or safety, results of a retrospective analysis presented at IDWeek 2013.

Pediatric linezolid-associated thrombocytopenia was associated with baseline renal impairment and low platelet values, underscoring the need “for a diligent risk-benefit assessment” in this population, reported at IDWeek 2013.